二零零五年,港大首次慶祝八位明德教授就職,為大學的歷史奠定重要的里程碑。
時至今日,已成立共一百一十九項明德教授席。
返回
徐維均先生

徐福全基金教授席 (分子醫學)

捐贈明德教授席,是紀念先父徐福全創業六十載及藉此回饋社會。分子醫學將會對人類各種疾病的了解及治療起重大作用。作為兩位醫生的父親,我樂於鼓勵和支持這方面的持續發展。 

徐維均先生

鄺沃林

鄺沃林

2011年就職

過去十年,分子醫學的發展在醫療護理界獲得重大進步。香港大學的專家對此領域的醫學知識貢獻卓著,專研利用新分子醫學技術診斷常見的遺傳性疾病,如血友病、地中海貧血症、杜氏肌營養不良症、脊髓性肌肉萎縮症、亨廷頓氏病,以及淋巴瘤、白血病等不同的血癌。

鄺沃林教授是醫學系血液、腫瘤內科及骨髓移植科主任。他的臨床研究重點是診治血癌,并擁有一支蜚聲國際的團隊,其治療T細胞和天然殺傷細胞淋巴瘤的水平處世界領先地位,而這種淋巴瘤在亞洲群族中屬於常見。

鄺教授專門研究分子致病途徑和血液腫瘤的新療法。目前他最著名的研究成果,是和他的臨床藥理學團隊,研發口服三氧化二砷治療急性早幼粒細胞白血病和其他血癌療法的發展和應用。

經過十年的發展,口服三氧化二砷成為首例完全在香港研發並在美國獲得專利的處方藥,是其他療法之外患者支付得起、容易取得的替代藥品。它對復發的急性早幼粒細胞白血病的緩解率接近100%。

砷常被認為是致命毒藥,但中醫應用這種元素長達幾個世紀,近來西醫也開始使用。經過細心研究,鄺教授率領團隊揭示三氧化二砷是一種有效的口服藥物。如果劑量正確,它比之前使用的替代藥品安全得多——靜脈注射三氧化二砷有嚴重的潛在毒性。事實上,口服療法被證實極其有效,以致在香港,它已經取代骨髓移植,成為急性早幼粒細胞白血病患者的標準療法,並應用於其他疾病,包括骨髓瘤和淋巴瘤。人們成立了一個國際口服三氧化二砷使用者小組,以推動此領域的臨床應用和研究。

除了獲得美國專利,鄺教授還獲得了三項臨時專利。他撰寫過4個圖書章節,在國際同行評議的雜誌中發表逾400篇原創文章,其中含27篇約稿。他是愛丁堡和格拉斯哥皇家醫學院院士,英國皇家病理學院院士,及香港醫學專科學院藥學和病理學院士。

前任明德教授

陳立怡

2008年就職
Molecular Medicine has been responsible for the major advances in Medicine in the past two decades. As part of the Department of Medicine, the Division of Molecular Medicine specializes in the development of novel diagnostic techniques for common genetic diseases such as thalassemias, haemophilias, Duchenne muscular dystrophy, spinal muscular atrophy and Huntington’s disease, including non-invasive prenatal diagnosis and pre-implantation genetic diagnosis.

The Division uses genome-wide scans with micro-satellite markers for linkage of new disease genes and develops DNA microarray technology for the diagnosis of genetic diseases and cancers and the elucidation of their molecular pathologies. It is responsible for the DNA based prenatal diagnosis service of all HA hospitals as well as the pre-implantation genetic diagnosis service. The Division is also conducting advanced work on the screening and early genetic diagnosis of cancer and hopes that this service will be widely adopted throughout Hong Kong.

Professor Chan, who received her doctorate from the University of London in 1973, has been instrumental in establishing DNA technology in Hong Kong and promoting the benefits of related research. Her work clearly demonstrates Molecular Medicine as a key area of research, that embraces many medical specialties.

Professor Chan, who started her career as a clinical biochemist in the Department of Chemical Pathology, St Bartholomew’s Hospital London, is responsible for establishing the first Prenatal Diagnosis Centre in South East Asia in 1982. For her outstanding contribution and commitment to the prevention and control of common genetic diseases she was awarded Honorary Fellowships of the Royal College of Physicians, London and the Hong Kong College of Physicians in 2001.

In addition, Professor Chan holds a number of other honorary appointments around the world including the Haemophilia Testing and Carrier Guidelines Faculty and Thalassemia Control Group at the World Health Organisation, Faculty for Haemophilia Control at the World Federation of Haemophilia as well as being an Expert Group Core member in the Global Burden of Diseases, a joint venture of the World Health Organisation, Harvard School of Public Health and the World Bank.

Locally, she was a member of the Biology & Medicine Panel of the Research Grants Council of the Hong Kong Government between 1995 and 2000 and currently sits on the Hospital Authority’s Central Committee on Clinical Genetics. She has also served in numerous university committees including the Genetic Manipulation Working Group, the steering committee of the Genome Research Centre, Project chairperson for the development of the New Medical Complex and Acting Director of the Institute of Molecular Biology.

Professor Chan has published 180 papers, including peer-reviewed research papers, book chapters and review articles. She has received many invitations as plenary and symposium speaker at international meetings and presented over 100 abstracts at international congresses. She is also guest editor and reviewer for many international journals.